Intellia Therapeutics Inc buy Guggenheim
Start price
12.05.25
/
50%
€7.88
Target price
12.05.26
€40.09
Performance (%)
50.25%
End price
13.05.26
€11.84
Summary
This prediction ended on 13.05.26 with a price of €11.84. The BUY prediction by Guggenheim for Intellia Therapeutics Inc saw massive gains of 50.25%. Guggenheim has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Intellia Therapeutics Inc | -4.970% | -4.970% | -15.436% |
| iShares Core DAX® | 1.717% | 3.368% | 5.887% |
| iShares Nasdaq 100 | -4.565% | -4.238% | 21.386% |
| iShares Nikkei 225® | -7.120% | -11.869% | 42.357% |
| iShares S&P 500 | -0.894% | 1.687% | 19.495% |
Comments by Guggenheim for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Guggenheim from $55.00 to $45.00. They now have a "buy" rating on the stock.
Ratings data for NTLA provided by MarketBeat
In the thread Trading Intellia Therapeutics Inc
Die von Guggenheim gewählte maximale Laufzeit wurde überschritten